DE69312077D1 - Behandlung von autoimmun- und entzundungskrankheiten - Google Patents

Behandlung von autoimmun- und entzundungskrankheiten

Info

Publication number
DE69312077D1
DE69312077D1 DE69312077T DE69312077T DE69312077D1 DE 69312077 D1 DE69312077 D1 DE 69312077D1 DE 69312077 T DE69312077 T DE 69312077T DE 69312077 T DE69312077 T DE 69312077T DE 69312077 D1 DE69312077 D1 DE 69312077D1
Authority
DE
Germany
Prior art keywords
autoimmune
pct
treatment
date
inflammation diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69312077T
Other languages
English (en)
Other versions
DE69312077T2 (de
Inventor
Marc Feldmann
Ravinder Nath Maini
Richard Owen Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kennedy Trust for Rheumatology Research
Original Assignee
Kennedy Institute of Rheumotology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kennedy Institute of Rheumotology filed Critical Kennedy Institute of Rheumotology
Application granted granted Critical
Publication of DE69312077D1 publication Critical patent/DE69312077D1/de
Publication of DE69312077T2 publication Critical patent/DE69312077T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
DE69312077T 1992-10-08 1993-10-06 Behandlung von autoimmun- und entzundungskrankheiten Expired - Lifetime DE69312077T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95824892A 1992-10-08 1992-10-08
PCT/GB1993/002070 WO1994008619A1 (en) 1992-10-08 1993-10-06 Treatment of autoimmune and inflammatory disorders

Publications (2)

Publication Number Publication Date
DE69312077D1 true DE69312077D1 (de) 1997-08-14
DE69312077T2 DE69312077T2 (de) 1997-10-30

Family

ID=25500778

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69312077T Expired - Lifetime DE69312077T2 (de) 1992-10-08 1993-10-06 Behandlung von autoimmun- und entzundungskrankheiten

Country Status (8)

Country Link
US (1) US5741488A (de)
EP (1) EP0663836B1 (de)
JP (1) JP3616091B2 (de)
AT (1) ATE155043T1 (de)
AU (1) AU5152293A (de)
CA (1) CA2146647C (de)
DE (1) DE69312077T2 (de)
WO (1) WO1994008619A1 (de)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5959087A (en) * 1989-08-07 1999-09-28 Peptide Technology, Ltd. Tumour necrosis factor binding ligands
US20030225254A1 (en) * 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
JP3443119B2 (ja) 1989-08-07 2003-09-02 ペプテック リミテッド 腫瘍壊死因子結合リガンド
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US7192584B2 (en) * 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US20040120952A1 (en) * 2000-08-07 2004-06-24 Centocor, Inc Anti-TNF antibodies and peptides of human tumor necrosis factor
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
DK0585705T3 (da) * 1992-08-28 1999-07-26 Bayer Ag Anvendelse af monoklone anti-TNF-antistoffer til behandling af bakteriel meningitis
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US6770279B1 (en) * 1992-10-08 2004-08-03 The Kennedy Institute Of Rheumatology TNFα antagonists and cyclosporin in therapy of rheumatoid arthritis
US20050255104A1 (en) * 1993-01-29 2005-11-17 Centocor, Inc. Methods of treating psoriasis using anti-TNF receptor fusion proteins
DE69405102T2 (de) 1993-06-03 1998-01-15 Therapeutic Antibodies Inc Antikoerperfragmente in therapie
AU6149594A (en) 1993-10-06 1995-05-01 Kennedy Institute For Rheumatology, The Treatment of autoimmune and inflammatory disorders
SK284040B6 (sk) * 1996-02-09 2004-08-03 Abbott Laboratories (Bermuda) Ltd. Ľudské protilátky k ľudskému TNFalfa, ich použitie, spôsob ich syntézy a farmaceutické prípravky s ich obsahom
US5916560A (en) * 1996-03-20 1999-06-29 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4/CD28/B7 pathways and compositions for use therewith
WO1998022137A1 (en) * 1996-11-15 1998-05-28 The Kennedy Institute Of Rheumatology SUPPRESSION OF TNF α AND IL-12 IN THERAPY
US6127387A (en) * 1996-12-10 2000-10-03 Thomas Jefferson University Use of CD4-binding small molecules to inhibit immune responses
DK1159003T3 (da) * 1999-03-02 2011-02-07 Centocor Inc Anti-tnfalfa-antistoffer til terapi af steroid-resistent astma
US20020077276A1 (en) * 1999-04-27 2002-06-20 Fredeking Terry M. Compositions and methods for treating hemorrhagic virus infections and other disorders
KR20020027311A (ko) 1999-05-07 2002-04-13 제넨테크, 인크. Ｂ 세포 표면 마커에 결합하는 길항물질을 이용한자가면역 질환의 치료
CA2781858C (en) 2000-05-12 2015-03-31 Genzyme Corporation Modulators of tnf-.alpha. signaling
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
US20110195063A1 (en) * 2000-08-07 2011-08-11 Centocor, Inc. Methods of Treating Ankylosing Spondylitis Using Anti-TNF Antibodies and Peptides of Human Tumor Necrosis Factor
US20050249735A1 (en) * 2000-08-07 2005-11-10 Centocor, Inc. Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor
US20060018907A1 (en) * 2000-08-07 2006-01-26 Centocor, Inc. Anti-TNF antibodies and peptides of human tumor necrosis factor
IL157706A0 (en) * 2001-03-02 2004-03-28 Medimmune Inc METHODS OF PREVENTING OR TREATING INFLAMMATORY OR AUTOIMMUNE DISORDERS BY ADMINISTERING INTEGRIN alphav beta3 ANTAGONISTS
TWI327597B (en) 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
US20050026854A1 (en) * 2001-11-05 2005-02-03 Young James William Selective elimination of cd52and uses thereof
RU2201255C1 (ru) * 2001-12-26 2003-03-27 Эпштейн Олег Ильич Лекарственное средство и способ регуляции сосудистого тонуса
US7211258B2 (en) * 2002-04-10 2007-05-01 Protalex, Inc. Protein A compositions and methods of use
US7425331B2 (en) * 2002-04-10 2008-09-16 Protalex, Inc. Protein A methods of use
JP2005535572A (ja) * 2002-04-12 2005-11-24 メディミューン，インコーポレーテッド 組換え抗インターロイキン−９抗体
UA76639C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
UA76640C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Спосіб корекції патологічних імунних реакцій та гомеопатичний лікарський засіб
UA76641C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP1562571B1 (de) 2002-11-21 2011-08-17 Genzyme Corporation Kombination von einem diamidderivat und immunsuppressiva zur unterdrückung der transplantatabstossung
DE60335652D1 (de) 2002-11-21 2011-02-17 Genzyme Corp Verwendung eines diamidderivats zur verhinderung der chronischen transplantatabstossung
ES2347239T3 (es) * 2002-12-02 2010-10-27 Amgen Fremont Inc. Anticuerpos dirigidos al factor de necrosis tumoral y usos de los mismos.
US20050042219A1 (en) * 2002-12-05 2005-02-24 Woulfe Susan L. Engineered Fab' fragment anti-tumor necrosis factor alpha in combination with disease modifying anti-rheumatic drugs
US7101978B2 (en) * 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
EP1460088A1 (de) 2003-03-21 2004-09-22 Biotest AG Humanisierter Antikörper gegen CD4 mit immunsuppressiven Merkmalen
ES2391087T3 (es) 2003-04-11 2012-11-21 Medimmune, Llc Anticuerpos de IL-9 recombinantes y usos de los mismos
US7435799B2 (en) * 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
JP5554466B2 (ja) 2004-03-01 2014-07-23 味の素株式会社 抗ヒトＴＮＦ−α抗体活性低下抑制剤
US7351739B2 (en) * 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
WO2006047639A2 (en) 2004-10-27 2006-05-04 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
US8119589B2 (en) 2004-11-12 2012-02-21 University Of North Carolina At Charlotte Modulation of CD4+ T cell responses by a tick saliva protein, Salp15 and polypeptides derived therefrom
HUE045710T2 (hu) 2005-05-18 2020-01-28 Ablynx Nv Javított, alfa tumor nekrózis faktor elleni nanobodies
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
CA2657581A1 (en) 2006-07-11 2008-01-17 Roy C. Levitt Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
EP3669878A1 (de) 2006-08-10 2020-06-24 Roy C. Levitt Lokalisierte therapie von entzündungskrankheiten der unteren atemwege mit hemmern für proinflammatorische zytokine
EP2737907A3 (de) 2007-05-07 2014-11-05 MedImmune, LLC Anti-Icos-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen
US20090038182A1 (en) * 2007-08-09 2009-02-12 Lans Maris J Footwear with built-in scale
JP5597553B2 (ja) 2008-03-13 2014-10-01 バイオテスト・アクチエンゲゼルシヤフト 疾患治療剤
CN102027016A (zh) 2008-03-13 2011-04-20 生物测试股份公司 一种治疗疾病的试剂
JP5604311B2 (ja) 2008-03-13 2014-10-08 バイオテスト・アクチエンゲゼルシヤフト 疾患治療剤
WO2010056804A1 (en) 2008-11-12 2010-05-20 Medimmune, Llc Antibody formulation
NZ592839A (en) * 2008-11-21 2012-10-26 Anthrogenesis Corp Treatment of diseases, disorders or conditions of the lung using placental cells
US20110071276A1 (en) * 2009-09-24 2011-03-24 Xbiotech, Inc. Method of modifying a monoclonal antibody
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
DE112011102358T5 (de) 2010-07-15 2013-04-25 Oleg Iliich Epshtein Verfahren zur Erhöhung der Wirkung einer aktivierten-potenzierten Form eines Antikörpers
MX2013000542A (es) 2010-07-15 2013-06-28 Oleg Iliich Epshtein Composicion farmaceutica combinada y metodos para el tratamiento de las enfermedades o condiciones funcionales del tracto gastrointestinal.
DE112011102412T5 (de) 2010-07-21 2013-07-04 Oleg Iliich Epshtein Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von mit Atemwegserkrankungen bzw. Atemwegsleiden assoziierten Erkrankungen bzw. Leiden
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9155784B2 (en) 2011-06-20 2015-10-13 Icahn School Of Medicine At Mount Sinai Anti-TNF-α therapy for the mucopolysaccharidoses and other lysosomal disorders
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
CA2883272A1 (en) 2012-09-02 2014-03-06 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695459A (en) * 1984-12-26 1987-09-22 The Board Of Trustees Of Leland Stanford Junior University Method of treating autoimmune diseases that are mediated by Leu3/CD4 phenotype T cells
US5096906A (en) * 1986-12-31 1992-03-17 University Of Virginia Alumni Patents Foundation Method of inhibiting the activity of leukocyte derived cytokines
GB8805792D0 (en) * 1988-03-11 1988-04-13 Celltech Ltd Medicaments
US5260422A (en) * 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
US5468481A (en) * 1988-06-23 1995-11-21 Amergen, Inc. MHC class II-peptide conjugates useful in ameliorating autoimmunity
US5298396A (en) * 1989-11-15 1994-03-29 National Jewish Center For Immunology And Respiratory Medicine Method for identifying T cells disease involved in autoimmune disease
GB9023783D0 (en) * 1990-11-01 1990-12-12 Celltech Ltd Pharmaceutical product
AU8910891A (en) * 1990-11-20 1992-06-11 National Heart & Lung Institute, The Treatment of lung diseases

Also Published As

Publication number Publication date
CA2146647A1 (en) 1994-04-28
WO1994008619A1 (en) 1994-04-28
US5741488A (en) 1998-04-21
DE69312077T2 (de) 1997-10-30
ATE155043T1 (de) 1997-07-15
AU5152293A (en) 1994-05-09
CA2146647C (en) 2009-05-05
EP0663836A1 (de) 1995-07-26
JP3616091B2 (ja) 2005-02-02
JPH08505365A (ja) 1996-06-11
EP0663836B1 (de) 1997-07-09

Similar Documents

Publication Publication Date Title
DE69312077D1 (de) Behandlung von autoimmun- und entzundungskrankheiten
DE69129800D1 (de) Behandlung von menschlichen retrovirus-infektionen mit 2',3'-dideoxyinosin
IT1261949B (it) Composizione terapeutica a base di interferone umano, impiego di interferone umano in tale composizione e relativo metodo.
DK0880350T3 (da) Behandling af dissemineret sklerose
DE69533040D1 (de) Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagien
ATE233738T1 (de) Kleine moleküle anwendbar in der behandlung von entzündgskrankheiten
DE69731540D1 (de) Behandlung von diarrhoe
ATE196847T1 (de) Verwendung von mannosephosphaten zur behandlung von fibrotischen störungen
ATE233091T1 (de) Verwendung von histamine-2 agonisten zur behandlung sexueller funktionsstörungen
ATE93138T1 (de) Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie.
DE69410254D1 (de) Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
DE69424777T2 (de) 3,4-diarylchromane zur behandlung von dermatitis
DE69834724D1 (de) Behandlung von Darm- oder Blasenentzündungen
NO894222D0 (no) Fremgangsmaater for behandling av profylakse av pneumocytis carinii pneumoni og andre sykdommer og forbindelser og formuleringer til anvendelse i nevnte metoder.
DE60029948D1 (de) Verbesserte methode zur behandlung von säugetieren mit geändertes säugetierblut
DE69623316T2 (de) Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen
DE69220939T2 (de) Gegengift immunsera
SE9502219D0 (sv) Novel medical use
EA199800859A1 (ru) Способ лечения при ядовитых укусах и ужалениях
DE69635282D1 (de) Behandlung der exzessiven aggressivität mit olanzapine
ATE213644T1 (de) Kombinationstherapie für die behandlung von arthritis erkrankungen
DE59603099D1 (de) Transdermales therapeutisches system für silatranverbindungen
MX9700626A (es) USO DE AZASPIRANOS EN LA REPARACIaN DE COMPOSICIONES PARA TRATAR INFECCIONES OPORTUNISTAS.
MX9605330A (es) Metodos y composiciones para el tratamiento de glomerulonefritis y otras enfermedades inflamatorias.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition